Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

>

The Phase IIa MIVI-IIT trial reported today was a sham injection controlled study in which patients were assigned to receive either 75ug or 125ug of microplasmin. A total of 30 patients across Europe were recruited to the study, of which 24 received microplasmin therapy while 6 received the sham injection. The trial showed clear benefits from therapy with 9 of the 24 microplasmin treated patients seeing resolution of their vitreomacular traction (including macular hole closure in 2 of the 4 macular hole cases) without the need for vitrectomy. In contrast, none of the 6 sham injected patients had resolution of their vitreomacular traction (including two patients with macular hole). The trial also showed that microplasmin therapy was safe and well tolerated. Given the excellent safety of microplasmin in the trial to-date, it has been decided to recruit a further 15 patients (12 treated and 3 sham) to evaluate a higher 175ug dose of the product to see if it will produce even better clinical outcomes.

Professor Peter Stalmans, the study's principal investigator, commented: "The results from the study that I will present at the ASRS meeting today clearly indicate the potential for microplasmin to become a more convenient, less invasive, hence more patient friendly treatment for vitreomacular traction. The fact that we have been able to clearly show that microplasmin can achieve clinically important outcomes such as traction release and macular hole closure without surgery augurs well for the future development of this novel treatment."

Prof. Desire Collen, CEO of ThromboGenics, commenting on today's results said: "The results of the microplasmin trial that we have announced today clearly show the drug's potential to treat a range of back of the eye diseases. The clinical benefits that we have seen in this study in conjunction with its excellent safety profile provide us with sound reasons for pushing ahead with the further clinical development of microp
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... According to the ... Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, Environmental, ... - Global Forecasts to 2019" published by ... at $896.5 Million in 2014 and is ... growing at a CAGR of 5.9% from ...
(Date:7/28/2014)... July 28, 2014 Immunomic Therapeutics, Inc. ... to further develop potential treatments for glioblastoma multiforme (GBM), ... combination with their patented vaccine platform, LAMP-vax. , ... are based on the work of John H. Sampson, ... The Preston Robert Tisch Brain Tumor Center at Duke ...
(Date:7/28/2014)... St Louis, MO (PRWEB) July 28, 2014 ... tools, software, and services that bring the power of ... for the inaugural Appistry Pipeline Challenge . ... Callum Bell, president of the National Center for Genome ... Children’s Mercy Hospitals and Clinics of Kansas City. Rounding ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The global ... billion by 2020, according to a new study by ... the rising demand for effective vaccines and drugs in ... unmet medical needs is expected to drive market demand ... to enhance agricultural productivity via the use of genetically ...
Breaking Biology Technology:Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... 1938 to the impact of the Krakatoa eruption of 1883, ... of extreme weather. Now an international team of climatologists have ... 1871 to the present day, and from the earth,s surface ... Reanalysis Project, outlined in the Quarterly Journal of the ...
... done and now they,ve done it. What,s more, they did ... U.S. Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... the first experimental demonstration of GRIN for gradient index ... a wide range of exotic optics, including superfast computers based ...
... Amgen (Nasdaq: AMGN ) today announced that it ... results on Monday, Jan. 24, 2011 after the close of ... conference call with the investment community at 2:00 p.m. Pacific ... Sharer, chairman and chief executive officer, and other members of ...
Cached Biology Technology:The 20th Century Reanalysis Project: A time machine for climate scientists 2The 20th Century Reanalysis Project: A time machine for climate scientists 3GRIN plasmonics 2GRIN plasmonics 3GRIN plasmonics 4Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results 2
(Date:7/28/2014)... of people in the United States have a circulatory ... can be painful and may even require surgery in ... muscle wasting and, in turn, limb amputation. , At ... (UTHealth) Medical School, scientists tested a non-surgical preventative treatment ... was associated with increased blood circulation. Their proof-of-concept ...
(Date:7/28/2014)... at Yale School of Medicine have pinpointed a mechanism in ... levels in the blood, linking it to both type 1 ... July 28 issue of Proceedings of the National Academies ... endopeptidase enzyme located in a part of the hypothalamus ... steps in motion that control glucose levels in the blood," ...
(Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Glucose 'control switch' in the brain key to both types of diabetes 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3
... be tough, but scientists have found a Yellowstone National ... simple one-celled algae called Cyanidioschyzon -- thrives ... occurs naturally around hot springs, said Tim McDermott, professor ... at Montana State University. Cyanidioschyzon could ...
... is a commonly used indicator organism for detecting the ... of E. coli as an indicator organism has ... this important microorganism in groundwater environments. Commonly only a single ... studies, yet research has shown that a significant amount of ...
... March 6, 2009 -- As the first plant life ... earth, bryophytes offer a unique opportunity for researchers to ... three varieties of bryophites (liverworts, hornworts, and mosses) have ... local environments, but with the recent effects of climate ...
Cached Biology News:Montana State team finds Yellowstone alga that detoxifies arsenic 2Montana State team finds Yellowstone alga that detoxifies arsenic 3Transport behavior of E. coli varies depending on manure source 2How increased UV exposure impacts plants 2
... increasingly essential for reducing sample and ... other biochemical applications. The eight-channel nano25 ... in the industry. ,Features: , ... dispensed volumes , Automated diagnostics detect ...
Request Info...
Collected from sexually mature rats....
...
Biology Products: